Amicus Therapeutics Is Set To Revolutionize The Treatment Of Genetic Disorders

In just 10 years, Amicus Therapeutics has risen to the forefront of the biotechnology industry with a fresh approach to the treatment of genetic disorders and illnesses. The company’s own website boasts a wide range of drug therapies designed to treat a spectrum of rare genetic disorders.
Among the company’s greatest achievements, Amicus Therapeutics has recently unveiled a treatment for Fabry disease, a rare genetic disorder named for Johannes Fabry. The new course of treatments will be also be used to treat Pompe disease and other Lysosomal Storage Disorders through enzyme replacement therapy.

https://www.facebook.com/pages/Amicus-Therapeutics/157577600941970
Developing a treatment plan for Lysosomal Storage Disorders is a tremendous advance, but it’s also the kind of thing this growing biotechnology company hopes to do regularly. Since its 2007 inception, Amicus Therapeutics has pledged to deliver the best possible treatments for people living with genetic diseases.
To maintain a vigilant focus on that directive, Amicus Therapeutics keeps a close eye on the community of families affected by rare and orphan genetic illnesses, providing them with support and offering new treatments, as they become available. In that vain, the biotechnology company is keeping an ear to the ground, looking for innovative ways to adapt new technologies and to outperform their own advances.
While Amicus Therapeutics’ own mission statement reveals a thirst for rapid advancement, the company is only limited by a desire for safety in their research and testing phases.
A code of conduct guides Amicus Therapeutics in all areas, from research and development to corporate decision making policies. A message from Patrik Florencio, Amicus Chief Compliance and Risk Officer, emphasizes that care for ethical actions on behalf of the company, ensuring that a concern for their patients won’t forsake greater concerns for the environments in which Amicus Therapeutics operates.
Speaking of their patients, Amicus Therapeutics takes their devotion to their patients into account, when considering new treatments. In searching for new treatments, Amicus collects research that will lead them toward more effective treatments for current and future patients. Incorporating patient input into developing each new therapy, Amicus Therapeutics remains at the forefront of the biotechnology industry .
Visit Amicus Therapeutics on Twitter or see job opportunities at Indeed

 

Reviewing The Contribution Of Penelope Kokkinides And Rick Shinto To InnovaCare Health

Healthcare provision in many countries is solely handled by the government and very few organs are left in the hands of the private companies. However, this may not be the best idea since the desired quality of care may not be handled by the government. The private healthcare industry has grown over the years with the introduction of new firms and new methods of dealing with problems.

When the government introduce Medicare Advantage, it opened new doors for private companies to venture into the field. Many companies that have invested in the area well are today established and performing well due to the huge number of clients served.

InnovaCare Health enjoys great support from users due to the high quality services the company offers. Incepted over 10years ago, InnovaCare Health went through a series of changes in leadership before the company landed in the hands of Rick Shinto, the CEO and President. Good leadership and insightful control has allowed InnovaCare Health to claim a bigger share of the market in the last five years.

About Rick Shinto and Penelope Kokkinides

InnovaCare Health has been built by many professionals, but the effort that Penelope Kokkinides and Rick Shinto put to developing the company cannot be overlooked. Rick Shinto is a graduate of medicine from the State University of Arizona.

He also holds an MBA from Redlands University and with his experience of over 20 years, he managed to author journals and articles supporting the development of unique and high quality healthcare systems.

He has been working on building InnovaCare Health since he joined the company to serve as the President and CEO in 2012. Rick Shinto enjoys the support and guidance of Penelope Kokkinides and the duo previously worked together at Aveta Inc from 2008 to 2012.

When they joined InnovaCare Health, they brought new energy and insight that has been steering the company to rank among the most established in the region.

InnovaCare Health

InnovaCare Health is a managed healthcare provider that serves the Puerto Rico. It currently stands among the best in the country and has managed to come up with new methods of tackling problems. InnovaCare Health works with established professionals who offer insight into the problems the company faces.

It is an established provider of Medicare Advantage plans with more than 200,000 users across North America. Most importantly, InnovaCare Health has been working on building a network that allows all clients to access easy support and better services.